EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models

Rongzhong Xu, Dongsheng Wang, Guangzhi Ma, Xun Yuan, Qian Chu, Songqing Fan, Rener Zhang, Pan Du, Shidong Jia, Ticiana A Leal, Suresh S Ramalingam, Zhen Chen und 1 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci197192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Rongzhong Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine…. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type II, Topoisomerase II Inhibitors, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Topoisomerases, Type IITopoisomerase II InhibitorsProto-Oncogene Proteins p21(ras)MutationSulfonamidesAnimalsHumansCell Line, TumorMiceDrug Resistance, NeoplasmPoly-ADP-Ribose Binding ProteinsApoptosisDNA DamageEtoposideXenograft Model Antitumor AssaysAntigens, NeoplasmPiperazinesPyridinesPyrimidines

Stichwörter der Autor:innen

ApoptosisCell biologyDrug therapyLung cancerOncology

Substanzen

DNA Topoisomerases, Type IITopoisomerase II InhibitorsProto-Oncogene Proteins p21(ras)Poly-ADP-Ribose Binding ProteinssotorasibKRAS protein, humanTOP2A protein, humanEtoposideSulfonamidesAntigens, Neoplasm

Autor:innen und Institutionen

  • Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Predicine, Inc., Hayward, California, USA.

Zitieren

APA

Xu, R., Wang, D., Ma, G., Yuan, X., Chu, Q., Fan, S., Zhang, R., Du, P., Jia, S., Leal, T. A., Ramalingam, S. S., Chen, Z., & Sun, S. Y. (2026). Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. Journal of Clinical Investigation. https://doi.org/10.1172/jci197192

Vancouver

Xu R, Wang D, Ma G, Yuan X, Chu Q, Fan S, et al. Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. Journal of Clinical Investigation. 2026. doi:10.1172/jci197192

BibTeX
@article{Xu2026,
  author = {Xu, Rongzhong and Wang, Dongsheng and Ma, Guangzhi and Yuan, Xun and Chu, Qian and Fan, Songqing and Zhang, Rener and Du, Pan and Jia, Shidong and Leal, Ticiana A and Ramalingam, Suresh S and Chen, Zhen and Sun, Shi-Yong},
  title = {Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci197192}
}
Kostenlos starten →